Navigation Links
Capgemini Releases New Study on Financial Impact of Masimo Noninvasive and Continuous Hemoglobin (SpHb(TM))
Date:4/16/2009

Hospital-wide Implementation of Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Could Generate Nearly $500,000 in Net Annual Cost Savings and Financial Gains

IRVINE, Calif., April 16, Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Capgemini, a leading supplier of global consulting and technology services, has released a study showing that a typical 500 bed hospital incorporating Masimo Rainbow SET Pulse CO-Oximetry into its clinical standards and care pathways could generate nearly $500,000 in net annual cost savings and financial gains.

Capgemini reported that significant financial benefits could be derived from incorporating noninvasive total hemoglobin (SpHb) by helping clinicians prevent unnecessary blood transfusions, identify internal bleeding earlier, and increase patient throughput. The study concluded that "whether considered on a per-patient, department, or hospital-wide analysis, there are significant clinical and financial benefits to implementing Pulse CO-Oximetry technology."

Masimo commissioned the Capgemini study for a third-party evaluation of the potential financial benefits of Masimo Rainbow SET. Hospital inputs were evaluated by Capgemini through 70 in-depth one-on-one interviews with clinicians and other decision-makers at 15 U.S. acute care hospitals and then quantified through a follow-on survey of 200 hospital-based physicians. The study found that the majority of anesthesiologists and two-thirds of surgeons believed that SpHb monitoring could prevent at least one unnecessary blood transfusion in every ten surgical cases on which it was used, contributing to $93,600 in net annual cost savings in a surgical department using 20 SpHb-enabled devices. The study also found that the majority of intensivists believed that SpHb monitoring could reduce intensive care length of stay by at least one day for every 15 or fewer patients on which it was used, contributing to $67,350 in net annual cost savings in an intensive care department using 10 SpHb-enabled devices.

Joe Kiani, Founder and CEO of Masimo, stated, "We believe that the Capgemini study will significantly aid hospitals seeking to evaluate the initial and ongoing investment in Masimo Rainbow SET by clearly identifying each of the various mechanisms by which SpHb can improve the clinical process of care and create net financial benefits."

The Capgemini study can be downloaded at www.masimo.com/capgemini. In addition, a customized financial analysis based on a hospital's own inputs incorporated into the Capgemini financial model is available upon request.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the accuracy and repeatability of the Capgemini financial model and results; risks related to our belief that the applications of Masimo Rainbow SET measurements described in the foregoing statements will deliver a sufficient level of clinical improvement over alternative measurement capabilities to create substantial financial benefits for hospitals, allow for rapid adoption of the technology, and materially increase market share and/or revenues for the company, as well as other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended January 3, 2009, filed with the Securities and Exchange Commission ("SEC") on March 4, 2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal year ended January 3, 2009, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Contact:
    Dana Banks
    Masimo Corporation
    949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation. Other trademarks used herein are the property of their respective owners.


'/>"/>
SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Glenwood Systems, LLC Releases EMR Practice Management and Medical Billing Process Improvement Program
2. Sentillion Releases Healthcare Do It Yourself Tool for Single Sign-On and Context Management Application Interfaces
3. Illinois Lottery Releases New MS Ticket, Dash! For Cash
4. U.S. Department of Health & Human Services Releases Public Service Announcements to Encourage Healthy Lifestyles
5. NIH releases the first research plan to reduce the burden of digestive diseases
6. APHA Releases Agenda for Health Reform
7. Pennsylvania Patient Safety Authority Releases March Advisory
8. Consumer Group Releases New Study About Defective Heart Devices and Implants; Patients Arrive in DC Tomorrow
9. Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results
10. HCLA Releases Report on Status of Medical Liability Reform
11. MayoClinic.com Releases New Design
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every ... the most heartfelt wishes of these children. The wishes provide hope and ... President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization ...
(Date:5/5/2016)... ... , ... Long Island’s fastest growing comprehensive eye care provider, North Shore ... Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage in ... partner of North Shore Eye Care. , “We are extremely proud to welcome ...
(Date:5/5/2016)... ... , ... TIME for Kids and The ZAC Foundation – a national leader ... nearly 1 million children with important water safety messages before summer break begins. ... accidental death in children one to 6 years of age. TIME for Kids ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week ... all over the United States to thank a nurse who's made a difference in ... $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) every ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology: